Inventiva 관리

관리 기준 확인 2/4

Inventiva CEO는 Frederic Cren, Jan2011 에 임명되었습니다 의 임기는 13.83 년입니다. 총 연간 보상은 € 1.00M, 30.4% 로 구성됩니다. 30.4% 급여 및 69.6% 보너스(회사 주식 및 옵션 포함). 는 € 13.81M 가치에 해당하는 회사 주식의 6.45% 직접 소유합니다. 13.81M. 경영진과 이사회의 평균 재임 기간은 각각 8.2 년과 7.8 년입니다.

주요 정보

Frederic Cren

최고 경영자

€1.0m

총 보상

CEO 급여 비율	30.4%
CEO 임기	13.8yrs
CEO 소유권	6.4%
경영진 평균 재임 기간	8.2yrs
이사회 평균 재임 기간	7.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Frederic Cren 의 보수는 Inventiva 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-€104m
Mar 31 2024	n/a	n/a	-€107m
Dec 31 2023	€1m	€305k	-€110m
Sep 30 2023	n/a	n/a	-€95m
Jun 30 2023	n/a	n/a	-€80m
Mar 31 2023	n/a	n/a	-€67m
Dec 31 2022	€878k	€300k	-€54m
Sep 30 2022	n/a	n/a	-€55m
Jun 30 2022	n/a	n/a	-€56m
Mar 31 2022	n/a	n/a	-€56m
Dec 31 2021	€929k	€299k	-€50m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€41m
Mar 31 2021	n/a	n/a	-€36m
Dec 31 2020	€388k	€267k	-€34m
Sep 30 2020	n/a	n/a	-€29m
Jun 30 2020	n/a	n/a	-€25m
Mar 31 2020	n/a	n/a	-€27m
Dec 31 2019	€374k	€243k	-€30m
Sep 30 2019	n/a	n/a	-€34m
Jun 30 2019	n/a	n/a	-€37m
Mar 31 2019	n/a	n/a	-€35m
Dec 31 2018	€376k	€243k	-€33m
Sep 30 2018	n/a	n/a	-€29m
Jun 30 2018	n/a	n/a	-€25m
Mar 31 2018	n/a	n/a	-€22m
Dec 31 2017	€372k	€243k	-€19m

보상 대 시장: Frederic 의 총 보상 ($USD 1.06M )은 German 시장( $USD 793.15K ).

보상과 수익: 회사가 수익성이 없는 동안 Frederic 의 보상이 증가했습니다.

CEO

Frederic Cren (58 yo)

13.8yrs

테뉴어

€1,003,699

보상

Mr. Frederic Cren has been Chief Executive Officer of Inventiva S.A. since co-founding Inventiva S.A. in 2011. Mr. Cren has been Chairman at Inventiva S.A. since May 31, 2016. He served as President of Inv...

리더십 팀

이름	위치	테뉴어	보상	소유권
Frederic Cren	Co-Founder	13.8yrs	€1.00m	6.45% € 13.8m
Pierre Broqua	Co-Founder	13.8yrs	€938.43k	4.46% € 9.6m
Jean Volatier	Deputy GM & CFO	12.3yrs	데이터 없음	0.17% € 368.5k
Alice Roudot-Ketelers	Chief Operating Officer	1.8yrs	데이터 없음	0.017% € 36.9k
Eric Duranson	General Counsel	3.3yrs	데이터 없음	0.017% € 36.9k
Nathalie Harroy	Head of Human Resources	12.8yrs	데이터 없음	0.075% € 161.6k
Kristina Meyer	Executive VP and Business Development & Alliance Management	no data	데이터 없음	데이터 없음
Michael Cooreman	Chief Medical Officer	4.1yrs	데이터 없음	0.017% € 36.9k
Pascaline Clerc	Executive Vice President of Strategy & Corporate Affairs	1.1yrs	데이터 없음	0.0086% € 18.4k

8.2yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 관리: 6IVA 의 관리팀은 노련하고 경험 (평균 재직 기간 8.2 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Frederic Cren	Co-Founder	8.5yrs	€1.00m	6.45% € 13.8m
Pierre Broqua	Co-Founder	8.5yrs	€938.43k	4.46% € 9.6m
Chris Buyse	Independent Director	7.8yrs	€61.20k	0% € 0
Annick Schwebig	Independent Director	7.8yrs	€61.20k	0.0035% € 7.6k
Jean-Louis Junien	Chairman of Scientific Advisory Board	no data	€16.00k	데이터 없음
Xiaoqin Lu	Independent Director	6.5yrs	€43.20k	데이터 없음
Heinz Maeusli	Independent Director	5.5yrs	€49.20k	데이터 없음
Sven Francque	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Manal Abdelmalek	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kenneth Cusi	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Glen Clack	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Gérard Zalcman	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음

7.8yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: 6IVA 의 이사회는 경험(평균 재직 기간 7.8 년)으로 간주됩니다.

Inventiva 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Recent updates

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Inventiva Provides Update on Development of cedirogant by AbbVie

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022

Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation

Inventiva Announces Positive Results of Clinical Thorough QT Study Conducted with Lanifibranor

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $30.00001 million.

Inventiva Announces the Initiation of Its Pivotal Phase III Clinical trial Evaluating Lanifibranor in NASH

Inventiva Announces Collaboration on Non-Invasive Biomarkers to Identify Patients Responding to Lanifibranor with Regards to Nash Resolution and Fibrosis Improvement

Inventiva S.A. to Report First Half, 2021 Results on Sep 20, 2021

Inventiva Announces Design of Phase III Clinical Trial with Lanifibranor in NASH

Inventiva Announces the Publication in the Journal of Hepatology of New Pre-Clinical Data Showing the Beneficial Effects of Lanifibranor on Cirrhosis

Inventiva S.A. Receives Positive Fda Feedback to Advance Its Lead Drug Candidate Lanifibranor into Pivotal Phase Iii in Nash

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Inventiva Receives Fda Fast Track Designation in Mps Vi for Its Clinical-Stage Asset Odiparci

Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH

Inventiva S.A. to Present the Results of Its Native Phase IIb Clinical Trial with Lanifibranor in Nash During Plenary Session at the Liver Meeting Digital Experience™ 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령